Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Receivables - Net (2020 - 2023)

Historic Receivables - Net for Rocket Pharmaceuticals (RCKT) over the last 4 years, with Q4 2023 value amounting to $50000.0.

  • Rocket Pharmaceuticals' Receivables - Net changed N/A to $50000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $50000.0, marking a year-over-year change of. This contributed to the annual value of $50000.0 for FY2023, which is N/A changed from last year.
  • Rocket Pharmaceuticals' Receivables - Net amounted to $50000.0 in Q4 2023.
  • Rocket Pharmaceuticals' 5-year Receivables - Net high stood at $1.6 million for Q2 2020, and its period low was $50000.0 during Q4 2023.
  • Its 4-year average for Receivables - Net is $964285.7, with a median of $1.0 million in 2021.
  • Per our database at Business Quant, Rocket Pharmaceuticals' Receivables - Net tumbled by 3750.0% in 2021 and then tumbled by 1000.0% in 2022.
  • Over the past 4 years, Rocket Pharmaceuticals' Receivables - Net (Quarter) stood at $1.1 million in 2020, then dropped by 9.09% to $1.0 million in 2021, then dropped by 10.0% to $900000.0 in 2022, then crashed by 94.44% to $50000.0 in 2023.
  • Its Receivables - Net stands at $50000.0 for Q4 2023, versus $900000.0 for Q1 2022 and $1.0 million for Q2 2021.